Methylation of the human papillomavirus-18 L1 gene: a biomarker of neoplastic progression?
Epigenetic transcriptional regulation plays an important role in the life cycle of human papillomaviruses (HPVs) and the carcinogenic progression of anogenital HPV associated lesions. We performed a study designed to assess the methylation status of the HPV-18 genome, specifically of the late L1 gene, the adjacent long control region (LCR), and part of the E6 oncogene in cervical specimens with a range of pathological diagnoses. In asymptomatic infections and infections with precancerous (precursor) lesions, HPV-18 DNA was mostly unmethylated, with the exception of four samples where hypermethylation of L1 was detected. In contrast, L1 sequences were strongly methylated in all cervical carcinomas, while the LCR and E6 remained unmethylated. HeLa cells, derived from a cervical adenocarcinoma, contain chromosomally integrated HPV-18 genomes. We found that L1 is hypermethylated in these cells, while the LCR and E6 are unmethylated. Treatment of HeLa cells with the methylation inhibitor 5-Aza-2'-deoxycytidine (5-Aza-CdR) led to the expected reduction of L1 methylation. After removal of 5-Aza-CdR, L1 methylation resumed and exceeded pretreatment levels. Unexpectedly, the LCR and E6 also became methylated under these conditions, albeit at lower levels than L1. We hypothesize that L1 is preferentially methylated after integration of the HPV genome into the cellular DNA, possibly since linearization prohibits its normal transcription, while the enhancer and promoter may be protected from methylation by transcription factors. Since our data suggest that HPV-18 L1 methylation can only be detected in carcinomas, except in some few precancerous lesions and asymptomatic infections, L1 methylation may constitute a powerful molecular marker for detecting this important step of neoplastic progression.
Department of Molecular Biology and Biochemistry, University of California Irvine, Irvine, CA 92697, USA.
Tolga
T
Turan
Mina
M
Kalantari
Itzel E
IE
Calleja-Macias
Heather A
HA
Cubie
Kate
K
Cuschieri
Luisa L
LL
Villa
Hanne
H
Skomedal
Hugo A
HA
Barrera-Saldaña
Hans-Ulrich
HU
Bernard
D001374:Azacitidine / Q000031:analogs & derivatives / Q000494:pharmacology; D014408:Biomarkers, Tumor; D036022:Capsid Proteins / Q000235:genetics*; D002584:Cervix Uteri / Q000821:virology; D019175:DNA Methylation; D015254:DNA Modification Methylases / Q000037:antagonists & inhibitors; D004279:DNA, Viral / Q000378:metabolism*; D004268:DNA-Binding Proteins / Q000235:genetics; D000077209:Decitabine; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005260:Female; D006367:HeLa Cells / Q000821:virology; D006801:Humans; D009856:Oncogene Proteins, Viral / Q000235:genetics; D027383:Papillomaviridae / Q000737:chemistry* / Q000302:isolation & purification; D011533:Proviruses / Q000737:chemistry; D050436:Regulatory Elements, Transcriptional; D002583:Uterine Cervical Neoplasms / Q000821:virology; D014764:Viral Proteins
D014408:Biomarkers, Tumor; D036022:Capsid Proteins; D004279:DNA, Viral; D004268:DNA-Binding Proteins; C052603:E6 protein, Human papillomavirus type 18; D004791:Enzyme Inhibitors; D009856:Oncogene Proteins, Viral; D014764:Viral Proteins; D000077209:Decitabine; D015254:DNA Modification Methylases; C480565:L1 protein, Human papillomavirus type 18; D001374:Azacitidine